ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » (1345–1364) Reproductive Issues in Rheumatic Disorders Poster II

Date: Monday, November 13, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

Abstract Number: 1345
Maternal and Infant Outcomes Following Abatacept Exposure During Pregnancy
Abstract Number: 1346
Semen Analysis of Patients with Psoriatic Arthritis, Axial Spondyloarthritis and Healthy Controls
Abstract Number: 1347
Continuing Biologic DMARDs During Pregnancy in Women with Rheumatic Disease Was Not Associated with Increased Unfavorable Pregnancy Outcomes, Serious Infections, and Adverse Effects of Vaccination
Abstract Number: 1348
Reproductive Outcomes for Women with Vasculitis
Abstract Number: 1349
Paternal Effects of Anti-TNFs in Inflammatory Arthritis
Abstract Number: 1350
Identification of ACR Guidelines for SLE Pregnancy Care in the Electronic Health Record
Abstract Number: 1351
HPV Vaccination in Adolescent and Young Adult Patients Seen in an Academic Rheumatology Center
Abstract Number: 1352
Similar Delivery Outcomes in Pregnant Patients with and Without Takayasu Arteritis – A Nationwide Inpatient Database Study
Abstract Number: 1353
Sexual Dysfunction in Women with Systemic Lupus Erythematosus: A Cross-Sectional Multicentre Study
Abstract Number: 1354
The Impact of Pregnancy Intention on Depression and Quality of Life in Women with Lupus
Abstract Number: 1355
Delivering Care for Pregnant Women with Rheumatic and Musculoskeletal Diseases in Ireland: Current Challenges and Practices
Abstract Number: 1356
Reproductive History and HPV Vaccination Awareness Among Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 1357
Systemic Lupus Erythematosus and Assisted Reproductive Technology: A Case Series and Systematic Literature Review
Abstract Number: 1358
Experiences and Attitudes Related to Assisted Reproductive Technologies Among Women with Systemic Rheumatic Disease
Abstract Number: 1359
Association of Menstrual Cycles and Disease Flare Activity in Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 1360
Factors Associated with Medication-related Concerns in Women with Inflammatory Rheumatic Diseases – an Analysis of a Nationwide Pregnancy Cohort
Abstract Number: 1361
Effect of Zen/Doria Remission and Glucocorticoid Dosage on the Pregnancy Outcome of SLE: Retrospective Study in Two Japanese Tertiary Referral Centers
Abstract Number: 1362
Improving Reproductive Health Counseling for Pediatric Adolescent Females Prescribed Teratogenic DMARDs
Abstract Number: 1363
Plasma Neutrophil Extracellular Trap Remnant Levels Are Lower in Premenopausal Healthy Women Using Oral Contraceptive Pills
Abstract Number: 1364
Both Low and High 25(OH)-Vitamin D Levels Increase Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology